Trial results show no survival benefit with the use of proton therapy in patients with advanced hepatocellular carcinoma

Initial results of the NRG Oncology NRG-GI003 clinical study comparing proton and photon therapy for patients with advanced hepatocellular carcinoma (HCC) indicate that proton therapy did not improve the primary objective of overall survival (OS). At the planned interim analysis, the trial was released for reporting after it crossed the futility boundary. Proton therapy also did not improve the trial's secondary endpoints, including progression-free survival (PFS) and local progression (LP).

Digital media health risks warrant global action to protect young people, experts argue

The way digital technologies are currently built and governed creates real risks to health worldwide, alongside genuine benefits, according to a new three-paper series authored by 13 global experts and published in The Lancet. The authors call for coordinated governance of digital systems, with the health and online safety of children and young people made an immediate global policy priority.

How blood vessels distinguish between growth and inflammation

The angiopoietin-Tie signaling pathway has long been known to be essential for the maturation and maintenance of healthy blood vessels. It stabilizes the vessel wall and regulates vascular growth during development. At the same time, it plays an important role in inflammation, when blood vessels become activated and immune cells leave the bloodstream and enter the surrounding tissue. How the same signaling pathway can control such different biological functions has remained unclear.

New technology advances understanding of eye pressure and glaucoma

For millions of people at risk of glaucoma, healthy eye pressure can mean the difference between preserving vision and losing it. Yet despite decades of research, scientists still do not fully understand what regulates daily changes in eye pressure or how those fluctuations may contribute to glaucoma. A series of three studies led by Christopher Passaglia, a University of South Florida professor and associate chair in the Department of Medical Engineering, is helping fill in those gaps.